The days of off-label speculation may soon be over for patients with the rare autoimmune disease MOGAD, as Roche’s Phase…

You’re reading the web version of DC Diagnosis, STAT’s twice-weekly newsletter about health and medical politics and policy. Sign up…

Andrew Bohm, M.D., chief strategist at Pfizer, is leaving his position two years after joining the New York drugmaker after…

AstraZeneca’s Ultomiris, already approved for the treatment of four rare diseases, has also shown potential in another rare disease, IgA…

WASHINGTON – The Trump administration will ask states to create new plans to verify health care workers paid by federally…